Last reviewed · How we verify
Azvudine
At a glance
| Generic name | Azvudine |
|---|---|
| Also known as | FNC, AZVUDINE 1 mg tablets, 4-amino-1-((2R,3S,4R,5R)-5-azido-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2(1H)-one, 1-(4-Azido-2-deoxy-2-fluoro-beta-D- arabino Ribo-furanosyl) cytosine, FNC, Placebo |
| Sponsor | Qianfoshan Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B (PHASE3)
- A Study to Evaluate the Pharmacokinetics and Safety of Azvudine Tablets in Healthy Adult Subjects and Healthy Elderly Subjects (PHASE1)
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Aluvia (PHASE1)
- [14C] Mass Balance Clinical Trial of Azvudine in Healthy Male Subjects (PHASE1)
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Dolutegravir Sodium Tablets (DTG) (PHASE1)
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Tenofovir Alafenol Fumarate Tablets (TAF) (PHASE1)
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rifampicin Capsules (RIF) (PHASE1)
- A Pharmacokinetics and Safety Study of Azvudine Tablets in Subjects With Mild-To-Moderate GFR Decline in Renal Insufficiency and in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |